Hrishikesh Patole

So quickly, our other expenses have declined sequentially as Y-o-Y. We had earlier highlighted in previous calls that in the post Revlimid area, we will be probably curtailing some cost and R&D if at all. So I mean, what's the major chunk that has gone awa y? And will this be likely a trend going forward quarterly on a quarterly basis?

And quickly on our NCE and date. So can you just throw on the 2, 3 names that we have on the pipeline and the progress as of now?

So, just quickly, what were the subsidiary sales in 3Q and for nine months as well? Can you just provide some numbers?

408. And for 3Q?

Okay, sir. And an y update you can provide on the Kothur site? Where do you stand with the process?